Orexo
Develops pharmaceuticals & digital health for opioid use disorder in the US market.
ORX | ST
Overview
Corporate Details
- ISIN(s):
- SE0000736415 (+2 more)
- LEI:
- 549300LJ5CCWDPTK9Z08
- Country:
- Sweden
- Address:
- Box 303, 751 05 UPPSALA
- Website:
- https://orexo.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Orexo is an international, commercial-stage pharmaceutical company specializing in the development of improved pharmaceuticals based on proprietary drug delivery technologies. With a 30-year history, the company creates innovative treatment solutions for significant medical needs. A primary focus for Orexo is the US market, where it commercializes drugs and digital mental health programs for patients suffering from opioid use disorder (OUD) and adjacent diseases. Through its robust product pipeline, Orexo is committed to addressing major public health challenges, including the opioid crisis.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2025-05-08 17:15 |
Report from Orexo AB’s annual general meeting 8 May 2025
|
English | 175.7 KB | ||
| 2025-05-08 17:15 |
Kommuniké från Orexo AB:s årsstämma den 8 maj 2025
|
Swedish | 148.7 KB | ||
| 2025-05-06 08:00 | Swedish | 4.6 MB | |||
| 2025-05-06 08:00 | English | 4.6 MB | |||
| 2025-04-02 19:30 |
Kallelse till årsstämma i Orexo
|
Swedish | 147.9 KB | ||
| 2025-03-28 08:00 | Swedish | 20.1 MB | |||
| 2025-02-06 08:00 | Swedish | 5.3 MB | |||
| 2025-02-06 08:00 | English | 5.3 MB | |||
| 2024-12-18 11:45 |
Kommuniké från Orexo AB:s extra bolagsstämma den 18 december 2024
|
Swedish | 124.4 KB | ||
| 2024-12-18 11:45 |
Report from Orexo AB’s extraordinary general meeting, December 18 2024
|
English | 127.1 KB | ||
| 2024-12-15 21:00 |
Orexo har löst patenttvisten mot Sun Pharmaceutical Industries för Zubsolv i USA
|
Swedish | 130.1 KB | ||
| 2024-12-15 21:00 |
Orexo resolves Zubsolv US patent litigation with Sun Pharmaceutical Industries
|
English | 135.7 KB | ||
| 2024-12-02 08:00 |
Orexo och GAIA överens om att avsluta partnerskapsavtalet för Deprexis®
|
Swedish | 179.7 KB | ||
| 2024-12-02 08:00 |
Orexo and GAIA agree to terminate the partnership for Deprexis®
|
English | 179.1 KB | ||
| 2024-11-21 18:00 |
Notice of Extraordinary General Meeting in Orexo AB (publ)
|
English | 188.2 KB |
Automate Your Workflow. Get a real-time feed of all Orexo filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Orexo
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Orexo via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2025-04-11 | Nikolaj Arrild Sørensen | Other | Buy | 2,460 | 35,178.00 SEK |
| 2025-04-04 | Nikolaj Arrild Sørensen | Other | Buy | 3,500 | 47,530.00 SEK |
| 2024-03-26 | Fredrik Järrsten | Other | Buy | 3,000 | 44,040.00 SEK |
| 2023-11-24 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 44,640.00 SEK |
| 2023-11-08 | Fredrik Järrsten | Other | Buy | 1,500 | 23,715.00 SEK |
| 2023-02-24 | Nikolaj Arrild Sørensen | Other | Buy | 11,500 | 188,945.00 SEK |
| 2023-01-27 | Fredrik Järrsten | Other | Buy | 4,500 | 79,695.00 SEK |
| 2022-07-26 | Michael Matly | Other | Buy | 2,820 | 60,777.77 SEK |
| 2022-07-21 | Charlotte Vithlani Hansson | Other | Buy | 3,000 | 61,500.00 SEK |
| 2022-07-15 | James Noble | Other | Buy | 18,500 | 394,252.80 SEK |
Peer Companies
